Bio-Rad showed resilience in certain areas such as process chromatography and digital PCR strategy, but faced challenges in the Life Science segment and gross margin declines. The company maintained its full-year guidance despite these challenges, indicating cautious optimism.
Company Guidance
During the Bio-Rad Third Quarter 2025 Results Conference Call, the company provided several key metrics and guidance for the year. Bio-Rad reported net sales of $653 million, a slight increase from $650 million in the third quarter of 2024, although on a currency-neutral basis, this represented a 1.7% year-over-year decrease. The Life Science segment reported $262 million in sales, flat compared to the previous year, with a 1.5% decline on a currency-neutral basis. Process chromatography showed strong performance with double-digit growth, but core Life Science revenue decreased 6% year-over-year. The Clinical Diagnostics segment had sales of $391 million, up 0.6% on a reported basis but down 1.8% currency-neutral, impacted by lower reimbursement rates for diabetes testing in China. Bio-Rad achieved a non-GAAP operating margin of 11.8%, improving from 11.3% in the prior year. Non-GAAP net income was $61 million, or $2.26 per diluted share, up from $56 million or $2.02 in Q3 2024. Free cash flow for the quarter was $89 million, down from $123 million in the previous year. The company maintained its full-year guidance for 2025, expecting currency-neutral revenue growth between flat and 1%, with non-GAAP gross and operating margins projected at 53.5% to 54.5% and 12% to 13%, respectively.
Strong Performance in Process Chromatography
Process chromatography experienced strong double-digit growth on a year-over-year basis due to the timing of customer orders within the quarter.
Progress in Droplet Digital PCR Strategy
Meaningful progress was made in advancing the Droplet Digital PCR strategy, including global sales training on new QX platforms and expanding partnerships with Gencurix and Biodesix.
Increase in Non-GAAP Operating Margin
Non-GAAP operating margin increased to 11.8% in Q3 2025 compared to 11.3% in Q3 2024, reflecting proactive cost management.
Maintained Full Year Guidance
Bio-Rad maintained its 2025 full year outlook with total currency-neutral revenue growth to be in the range of flat to 1%.
Bio-Rad Laboratories (BIO) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BIO Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 29, 2025
$319.47
$304.61
-4.65%
Jul 31, 2025
$241.95
$284.60
+17.63%
May 01, 2025
$240.43
$236.34
-1.70%
Feb 13, 2025
$306.36
$277.16
-9.53%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bio-Rad Laboratories (BIO) report earnings?
Bio-Rad Laboratories (BIO) is schdueled to report earning on Feb 12, 2026, After Close (Confirmed).
What is Bio-Rad Laboratories (BIO) earnings time?
Bio-Rad Laboratories (BIO) earnings time is at Feb 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.